Cereal giant Sanitarium and retailer Rebel Sports are challenging a decision dismissing proceedings against a UK marketing company amid a contractual dispute over a recent joint promotional campaign.
ObjectiVision has presented a “limited” and “debatable” case that its source code for a glaucoma testing device was copied, the Federal Court heard Thursday as the trial in a four-year spat with the University of Sydney over IP rights came to a close.
A subsidiary of car leasing company McMillan Shakespeare faces a class action over vehicle warranties that gave the company “complete and unfettered” discretion to reject claims by customers.
Motorola Solutions says Hytera Communications misled the Federal Court about key decision makers involved in the development of radio products which it claims infringe three of its patents.
TPI Enterprises has gone on the offensive in a patent lawsuit initiated by rival poppy processor Tasmanian Alkaloids, saying the patents at the centre of the suit describe natural parts that can’t be patented.
Concerns that the proposed acquisition of Sirtex Medical by a Chinese private equity firm would leave the company with insufficient funds to cover a settlement or judgement in a class action were eased Wednesday, after a barrister said the takeover would leave the company with just under $1 billion in assets.
The company that manufactures Botox alternatives has denied infringing on Allergan’s Botox trade mark, telling a court Wednesday its use of the word was for comparative purposes only.
Private equity firm Adcock has won almost $1 million in a judgment against the former boss of Aussie Home Loans, Stephen Porges, who was found to have misled the firm over the profitability of shares in a digital commerce startup he wanted to offload.
Facing the possibility of more class actions related its use of allegedly toxic firefighting foam at military bases throughout Australia, the Commonwealth has turned to one of the country’s largest firms for its defence in the two most recently filed cases.
Ophthalmic diagnostic device manufacturer ObjectiVision has made its final pitch to the Federal Court at the end of trial in a long-running intellectual property and contract dispute with the University of Sydney, saying in closing submissions that the school had run a “curious” case.